AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 1453728 — intervention group
Group type: COMPARATOR
Intervention: Standard perfusion (NP)
Number of subjects: 100
Study 6230173 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticlopidine (250 mg bid for 14 days)
Number of subjects: 10
Study 6230173 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 6230173 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticlopidine
Number of subjects: 10
Study 30835822 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-operative dexmedetomidine (0.5 µg.kg-1 bolus followed by 0.4 µg.kg-1.hr-1 infusion)
Number of subjects: 535
Study 30835822 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 535
Study 30701937 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard triple therapy (omeprazole, amoxicillin, clarithromycin)
Number of subjects: 180
Study 30701937 — intervention group
Group type: EXPERIMENTAL
Intervention: Four-component therapy with bismuth (omeprazole, tetracycline, metronidazole, bismuth tricalium dicitrate)
Number of subjects: 180
Study 30701937 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid scheme (first 5 days: omeprazole and amoxicillin, next 5 days: omeprazole, amoxicillin, clarithromycin, metronidazole)
Number of subjects: 180
Study 26809143 — intervention group
Group type: EXPERIMENTAL
Intervention: Familiar vegetable (carrot)
Number of subjects: 95
Study 26809143 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel vegetable (celeriac)
Number of subjects: 95
Study 26809143 — intervention group
Group type: EXPERIMENTAL
Intervention: Younger children
Number of subjects: 95
Study 26809143 — intervention group
Group type: EXPERIMENTAL
Intervention: Older children
Number of subjects: 95
Study 23548526 — intervention group
Group type: EXPERIMENTAL
Intervention: Ecallantide (30 mg single dose)
Number of subjects: 179
Study 22232815 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous reduction (PR) and calcium sulfate cement (CSC) grafting
Number of subjects: 90
Study 22232815 — intervention group
Group type: COMPARATOR
Intervention: Open reduction and internal fixation (ORIF)
Number of subjects: 90
Study 22232815 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous reduction (PR)
Number of subjects: 90
Study 19230758 — intervention group
Group type: EXPERIMENTAL
Intervention: Algorithm-calculated CPAP pressure (mean 7.0 cmH2O)
Number of subjects: 69
Study 19230758 — intervention group
Group type: EXPERIMENTAL
Intervention: Auto-CPAP titration (optimal pressure 7.0 cmH2O)
Number of subjects: 69
Study 16319211 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual stimuli visible only to short‐wave‐sensitive cones (S cones)
Number of subjects: 0
Study 16319211 — intervention group
Group type: COMPARATOR
Intervention: Luminance pathways
Number of subjects: 0
Study 14604599 — intervention group
Group type: EXPERIMENTAL
Intervention: Early shift (awakening: 04:00-05:30 h)
Number of subjects: 55
Study 14604599 — intervention group
Group type: EXPERIMENTAL
Intervention: Late shift (awakening: 06:00-09:00 h)
Number of subjects: 55
Study 14604599 — intervention group
Group type: EXPERIMENTAL
Intervention: Night shift (awakening: 11:00-14:00 h)
Number of subjects: 55
Study 14604599 — intervention group
Group type: COMPARATOR
Intervention: Students after short nap (awakening: 18:45-20:30 h)
Number of subjects: 55
Study 11770253 — intervention group
Group type: EXPERIMENTAL
Intervention: Opiate maintenance program
Number of subjects: 175
Study 11770253 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 175
Study 9167026 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutrophil autoantibodies (ANCA) detection in patients with IBD
Number of subjects: 500
Study 1540729 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 40
Study 1540729 — intervention group
Group type: COMPARATOR
Intervention: Metoprolol
Number of subjects: 40
Study 3873834 — intervention group
Group type: EXPERIMENTAL
Intervention: Hexabrix
Number of subjects: 40
Study 3873834 — intervention group
Group type: COMPARATOR
Intervention: Renografin-60
Number of subjects: 40
Study 29376434 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic, resistive, and Tai Chi exercise for 8 weeks to 12 months
Number of subjects: 16
Study 29376434 — intervention group
Group type: COMPARATOR
Intervention: Physical activity (non-interventional studies)
Number of subjects: 16
Study 29016275 — intervention group
Group type: COMPARATOR
Intervention: Combined Behavioral Intervention (CBI)
Number of subjects: 215
Study 29016275 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoanalytic-Interactional Therapy (PIT)
Number of subjects: 215
Study 27134145 — intervention group
Group type: EXPERIMENTAL
Intervention: Concomitant treatment (esomeprazole 40mg, amoxicillin 1g/bid for 5 days, followed by 5 days of esomeprazole 40mg, clarithromycin 500mg and metronidazole 500mg bid for 10 days)
Number of subjects: 353
Study 27134145 — intervention group
Group type: COMPARATOR
Intervention: Sequential treatment (same drugs as concomitant but taken sequentially)
Number of subjects: 353
Study 27134145 — intervention group
Group type: EXPERIMENTAL
Intervention: Concomitant treatment
Number of subjects: 353
Study 27134145 — intervention group
Group type: COMPARATOR
Intervention: Sequential treatment
Number of subjects: 353
Study 27134145 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 353
Study 25352299 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined Diet Dialysis Program (CDDP)
Number of subjects: 68
Study 25352299 — intervention group
Group type: COMPARATOR
Intervention: Standard thrice-a-week hemodialysis (THD)
Number of subjects: 68
Study 22503778 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual feedback group
Number of subjects: 2
Study 22503778 — intervention group
Group type: COMPARATOR
Intervention: Auditory feedback group
Number of subjects: 2
Study 22503778 — intervention group
Group type: COMPARATOR
Intervention: Removal of feedback
Number of subjects: 2
Study 20198405 — intervention group
Group type: EXPERIMENTAL
Intervention: Cemented Charnley cup
Number of subjects: 215
Study 20198405 — intervention group
Group type: EXPERIMENTAL
Intervention: Uncemented Duraloc 1200 cup
Number of subjects: 215
Study 20198405 — intervention group
Group type: COMPARATOR
Intervention: Cemented Charnley cup and Uncemented Duraloc 1200 cup
Number of subjects: 215
Study 19094439 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefuroxime-sulbactam
Number of subjects: 75
Study 19094439 — intervention group
Group type: COMPARATOR
Intervention: Amoxicillin-clavulanic acid
Number of subjects: 75
Study 16213401 — intervention group
Group type: EXPERIMENTAL
Intervention: Occlusive patching
Number of subjects: 30
Study 16213401 — intervention group
Group type: COMPARATOR
Intervention: Driving monocularly (with patching)
Number of subjects: 30
Study 11801507 — intervention group
Group type: EXPERIMENTAL
Intervention: Scanning laser polarimeter (GDx; GDx Nerve Fiber Analyzer)
Number of subjects: 184
Study 10078856 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% aminophylline cream (AC)
Number of subjects: 9
Study 10078856 — intervention group
Group type: COMPARATOR
Intervention: no cream (NC)
Number of subjects: 9
Study 10078856 — intervention group
Group type: COMPARATOR
Intervention: placebo cream (PC)
Number of subjects: 9
Study 7484326 — intervention group
Group type: EXPERIMENTAL
Intervention: Binge-prone group
Number of subjects: 126
Study 7484326 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 126
Study 7484326 — intervention group
Group type: EXPERIMENTAL
Intervention: Binge-prone women in the presence of food they enjoyed
Number of subjects: 126
Study 2397758 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased inertial load
Number of subjects: 0
Study 2397758 — intervention group
Group type: EXPERIMENTAL
Intervention: Decreased inertial load
Number of subjects: 0
Study 2397758 — intervention group
Group type: COMPARATOR
Intervention: Control condition (no unexpected load change)
Number of subjects: 0
Study 434004 — intervention group
Group type: EXPERIMENTAL
Intervention: Crystalline arborization test
Number of subjects: 25
Study 434004 — intervention group
Group type: COMPARATOR
Intervention: Urine samples
Number of subjects: 25
Study 30429415 — intervention group
Group type: EXPERIMENTAL
Intervention: Gefitinib plus bevacizumab (GEF+BEV group)
Number of subjects: 0
Study 30429415 — intervention group
Group type: COMPARATOR
Intervention: Gefitinib (GEF group)
Number of subjects: 0
Study 28335664 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy intervention (CBTi)
Number of subjects: 84
Study 28335664 — intervention group
Group type: COMPARATOR
Intervention: Telephone Counseling (TC)
Number of subjects: 84
Study 25599147 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuromuscular blocking agents
Number of subjects: 17
Study 23456540 — intervention group
Group type: EXPERIMENTAL
Intervention: Mothers and Babies (MB) Course
Number of subjects: 78
Study 23456540 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 78
Study 21832111 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomiphene citrate
Number of subjects: 626
Study 21832111 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 626
Study 21832111 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined (Clomiphene citrate + Metformin)
Number of subjects: 626
Study 19602916 — intervention group
Group type: COMPARATOR
Intervention: Not available
Number of subjects: 0
Study 17357903 — intervention group
Group type: EXPERIMENTAL
Intervention: Pneumatic compression (FemoStop system)
Number of subjects: 2085
Study 17357903 — intervention group
Group type: COMPARATOR
Intervention: Manual compression
Number of subjects: 2085
Study 15289792 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoconazole (400 mg)
Number of subjects: 13
Study 11715169 — intervention group
Group type: EXPERIMENTAL
Intervention: Influenza vaccine (0.5 mL containing A/Wuhan/359/95 (H3N2), A/Texas/36/91 (H1N1), B/Beijing/184/93)
Number of subjects: 493
Study 11715169 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 493
Study 11715169 — intervention group
Group type: EXPERIMENTAL
Intervention: Influenza vaccine
Number of subjects: 493
Study 9570259 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 or 30 mg lansoprazole/day
Number of subjects: 111
Study 9570259 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg omeprazole/day
Number of subjects: 111
Study 8056998 — intervention group
Group type: EXPERIMENTAL
Intervention: lorazepam 0.5 mg
Number of subjects: 50
Study 8056998 — intervention group
Group type: EXPERIMENTAL
Intervention: lorazepam 0.75 mg
Number of subjects: 50
Study 8056998 — intervention group
Group type: EXPERIMENTAL
Intervention: lorazepam 1 mg
Number of subjects: 50
Study 8056998 — intervention group
Group type: EXPERIMENTAL
Intervention: lorazepam up to 1.5 mg
Number of subjects: 50
Study 8056998 — intervention group
Group type: EXPERIMENTAL
Intervention: lorazepam
Number of subjects: 50
Study 8056998 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 50
Study 3383875 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol 100 mg b.i.d. (n = 154)
Number of subjects: 301
Study 3383875 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 147)
Number of subjects: 301
Study 3383875 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol 100 mg b.i.d.
Number of subjects: 301
Study 3383875 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 301
Study 31127676 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid 0.8 mg daily for 3 months
Number of subjects: 0
Study 31127676 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 3 months
Number of subjects: 0
Study 31786810 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine
Number of subjects: 2226
Study 31786810 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Number of subjects: 2226
Study 31786810 — intervention group
Group type: EXPERIMENTAL
Intervention: Levobupivacaine
Number of subjects: 2226
Study 31786810 — intervention group
Group type: EXPERIMENTAL
Intervention: Prilocaine
Number of subjects: 2226
Study 31786810 — intervention group
Group type: EXPERIMENTAL
Intervention: Procaine
Number of subjects: 2226
Study 31786810 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Number of subjects: 2226
Study 31786810 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-Chloroprocaine
Number of subjects: 2226
Study 31786810 — intervention group
Group type: EXPERIMENTAL
Intervention: Mepivacaine
Number of subjects: 2226
Study 28715540 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyridoxine (200 mg daily for a maximum of 8 cycles of capecitabine)
Number of subjects: 210
Study 28715540 — intervention group
Group type: COMPARATOR
Intervention: Placebo (daily for a maximum of 8 cycles of capecitabine)
Number of subjects: 210
Study 28715540 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyridoxine and Placebo (both arms)
Number of subjects: 210
Study 25137370 — intervention group
Group type: EXPERIMENTAL
Intervention: Interval training group
Number of subjects: 14
Study 25137370 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 14
Study 24026257 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based intervention delivered by social workers
Number of subjects: 208
Study 24026257 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 208
Study 20185003 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose dobutamine response (10 microg/kg/min)
Number of subjects: 69
Study 20185003 — intervention group
Group type: EXPERIMENTAL
Intervention: Microvascular obstruction (MVO)
Number of subjects: 69
Study 20185003 — intervention group
Group type: EXPERIMENTAL
Intervention: Relative delayed enhancement extent (DE)
Number of subjects: 69
Study 20185003 — intervention group
Group type: EXPERIMENTAL
Intervention: Transmural DE pattern (TMDE)
Number of subjects: 69
Study 18388122 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium Carbonate (CC) 500 mg
Number of subjects: 12
Study 18388122 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevelamer Hydrochloride (SEV) 800 mg
Number of subjects: 12
Study 18388122 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 15898218 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated system with recommendation to prescribe angiotensin‐converting enzyme inhibitors or angiotensin II receptor blockers
Number of subjects: 4000
Study 15898218 — intervention group
Group type: COMPARATOR
Intervention: Control group with no recommendation
Number of subjects: 4000
Study 15898218 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated system with recommendation to prescribe statins
Number of subjects: 4000
Study 15898218 — intervention group
Group type: COMPARATOR
Intervention: Control group with no recommendation for statins
Number of subjects: 4000
Study 12534414 — intervention group
Group type: EXPERIMENTAL
Intervention: Alosetron (1 mg b.d.)
Number of subjects: 15
Study 12534414 — intervention group
Group type: COMPARATOR
Intervention: Placebo (b.d.)
Number of subjects: 15
Study 10368502 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol (50 microgram intravaginally every 4 hours)
Number of subjects: 159
Study 10368502 — intervention group
Group type: COMPARATOR
Intervention: Prepidil (0.5 mg intracervically every 6 hours)
Number of subjects: 159
Study 10368502 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol
Number of subjects: 159
Study 10368502 — intervention group
Group type: COMPARATOR
Intervention: Prepidil
Number of subjects: 159
Study 8905421 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide
Number of subjects: 16
Study 8905421 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerosolized prostacyclin
Number of subjects: 16
Study 1702812 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone (60 mg/day for 3 days)
Number of subjects: 9
Study 1702812 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 1702812 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone
Number of subjects: 9
Study 6276584 — intervention group
Group type: EXPERIMENTAL
Intervention: β-endorphin 2 mg intrathecally
Number of subjects: 20
Study 6276584 — intervention group
Group type: EXPERIMENTAL
Intervention: morphine HCl 0.2 mg intrathecally
Number of subjects: 20
Study 6276584 — intervention group
Group type: COMPARATOR
Intervention: Control group (halothane-N2O anesthesia)
Number of subjects: 20
Study 31449470 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy (NAC) with cisplatin and gemcitabine followed by standard chemoradiation (CRT)
Number of subjects: 107
Study 31449470 — intervention group
Group type: COMPARATOR
Intervention: Standard chemoradiation (CRT) alone
Number of subjects: 107
Study 28543873 — intervention group
Group type: EXPERIMENTAL
Intervention: Parathyroidectomy (PTX)
Number of subjects: 191
Study 28543873 — intervention group
Group type: COMPARATOR
Intervention: Observation (OBS)
Number of subjects: 191
Study 26341118 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin
Number of subjects: 41
Study 26341118 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study 23715821 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertaconazole 2 % cream
Number of subjects: 60
Study 23715821 — intervention group
Group type: COMPARATOR
Intervention: Pimecrolimus 1 % cream
Number of subjects: 60
Study 22832429 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram treatment for 8 weeks
Number of subjects: 63
Study 22832429 — intervention group
Group type: COMPARATOR
Intervention: Post-mortem brain samples from MDD subjects
Number of subjects: 63
Study 20008582 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticipatory and Preventive Team Care (APTCare)
Number of subjects: 241
Study 20008582 — intervention group
Group type: COMPARATOR
Intervention: Usual care from family physicians
Number of subjects: 241
Study 16923461 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel 600 mg loading dose
Number of subjects: 45
Study 16923461 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel 900 mg loading dose
Number of subjects: 45
Study 16923461 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel 300 mg loading dose
Number of subjects: 45
Study 16923461 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel cessation
Number of subjects: 45
Study 12908110 — intervention group
Group type: EXPERIMENTAL
Intervention: Two embryos (Group 1)
Number of subjects: 169
Study 12908110 — intervention group
Group type: COMPARATOR
Intervention: Three embryos (Group 2)
Number of subjects: 169
Study 11521332 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid, lipid-lowering drugs, vitamins, and exercise (primary preventive effects)
Number of subjects: 0
Study 11521332 — intervention group
Group type: EXPERIMENTAL
Intervention: Reducing triglyceride levels or abdominal obesity
Number of subjects: 0
Study 11521332 — intervention group
Group type: EXPERIMENTAL
Intervention: Angina as a non-specific symptom
Number of subjects: 0
Study 9072600 — intervention group
Group type: EXPERIMENTAL
Intervention: Double freeze-thaw cycle
Number of subjects: 150
Study 9072600 — intervention group
Group type: COMPARATOR
Intervention: Single freeze-thaw cycle
Number of subjects: 150
Study 9072600 — intervention group
Group type: EXPERIMENTAL
Intervention: Salvage cryotherapy (overall)
Number of subjects: 150
Study 8430362 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative radiotherapy after curative resection (CR + R)
Number of subjects: 130
Study 8430362 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative radiotherapy after palliative resection (PR + R)
Number of subjects: 130
Study 8430362 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative radiotherapy (CR + R and PR + R)
Number of subjects: 130
Study 8430362 — intervention group
Group type: COMPARATOR
Intervention: Control group after curative resection (CR)
Number of subjects: 130
Study 8430362 — intervention group
Group type: COMPARATOR
Intervention: Control group after palliative resection (PR)
Number of subjects: 130
Study 2888072 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational program intervention
Number of subjects: 403
Study 2888072 — intervention group
Group type: COMPARATOR
Intervention: Control group (nonintervention)
Number of subjects: 403
Study 31751758 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine laboratory screening for secondary causes of CSU
Number of subjects: 0
Study 31751758 — intervention group
Group type: COMPARATOR
Intervention: No testing approach
Number of subjects: 0
Study 31751758 — intervention group
Group type: EXPERIMENTAL
Intervention: Antihistamine therapy
Number of subjects: 0
Study 31751758 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclospirine therapy
Number of subjects: 0
Study 28941141 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg of ortho-silicic acid stabilized by hydrolyzed collagen (group 1)
Number of subjects: 22
Study 28941141 — intervention group
Group type: COMPARATOR
Intervention: Placebo (group 2)
Number of subjects: 22
Study 27207965 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid uptitration protocol
Number of subjects: 46
Study 27207965 — intervention group
Group type: COMPARATOR
Intervention: Prolonged uptitration protocol
Number of subjects: 46
Study 27207965 — intervention group
Group type: COMPARATOR
Intervention: Standard clinical practice
Number of subjects: 46
Study 25030264 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine treatment
Number of subjects: 25
Study 25030264 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 25
Study 22944873 — intervention group
Group type: EXPERIMENTAL
Intervention: Early integrated treatment group (ART within 4 weeks of tuberculosis treatment initiation)
Number of subjects: 642
Study 22944873 — intervention group
Group type: COMPARATOR
Intervention: Late integrated treatment group (ART within 4 weeks of completion of the intensive phase of tuberculosis treatment)
Number of subjects: 642
Study 22944873 — intervention group
Group type: COMPARATOR
Intervention: Sequential treatment group (ART within 4 weeks after tuberculosis therapy completion)
Number of subjects: 642
Study 20090313 — intervention group
Group type: EXPERIMENTAL
Intervention: Pullulan (12 g/day)
Number of subjects: 20
Study 20090313 — intervention group
Group type: EXPERIMENTAL
Intervention: Promitor Resistant Starch (12 g/day)
Number of subjects: 20
Study 20090313 — intervention group
Group type: EXPERIMENTAL
Intervention: Soluble fiber dextrin (12 g/day)
Number of subjects: 20
Study 20090313 — intervention group
Group type: EXPERIMENTAL
Intervention: Promitor Soluble Corn Fiber (12 g/day)
Number of subjects: 20